Key result
Admission NGAL >134 ng/ml links to ~75% higher death risk and worsening renal function in AHF.
Why the study?
Does admission plasma NGAL predict in-hospital worsening renal function and post-discharge adverse outcomes in patients with acute heart failure?
Cohort
Does admission plasma NGAL predict in-hospital worsening renal function and post-discharge adverse outcomes in patients with acute heart failure?
Hazard Ratio: 1.75 (95% CI 1.24–2.45)
p-value: p=< 0.001
Admission NGAL is a useful biomarker for predicting in-hospital worsening renal function and 6-month mortality in patients with acute heart failure.
NGAL may aid WRF risk stratification in acute HF; leaves open its incremental value over routine markers in guiding care.
UNLABELLED: Abstract Background: The role of neutrophil gelatinase-associated lipocalin (NGAL) has been described in chronic heart failure (HF), however less data are available in patients admitted for acute HF. METHODS: We evaluated the role of NGAL in predicting in-hospital worsening renal function (WRF) and post-discharge follow-up during six months period in patients with acute HF. All patients were submitted to creatinine, estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN) and B-type natriuretic peptide (BNP) measurement during hospitalization and before discharge. RESULTS: Patients with chronic kidney dysfunction (CKD) demonstrated higher NGAL respect to subject with preserved renal function (241 ± 218 and 130 ± 80 ng/ml; P = 0.0001). In subgroup that developed WRF during hospitalization, NGAL levels were significantly increased respect to patients without WRF (272 ± 205 versus 136 ± 127 ng/ml; P = 0.0001). A cut off of 134 ng/ml has been related to WRF with good sensibility and specificity (92% and 71% AUC 0.83; P = 0.001). Multivariable Cox regression analysis showed that cut-off of 134 ng/ml was the only marker related to death (HR: 1.75; 95% CI: 1.24-2.45; P < 0.001). Follow-up analysis confirmed that NGAL > 130 ng/ml was associated with adverse events during a six-month period. CONCLUSION: Admission NGAL measurement appears a sensible tool for in-hospital WRF prediction as well as an early marker for adverse outcome during post discharge vulnerable phase.
No takes yet. Share an insight, caveat, or question.
Palazzuoli et al. (2014) conducted a cohort in Acute heart failure. Admission plasma NGAL > 134 ng/ml vs. NGAL ≤ 134 ng/ml was evaluated on Death (HR 1.75, 95% CI 1.24-2.45, p=< 0.001). Admission NGAL > 134 ng/ml was significantly associated with an increased risk of death (HR 1.75; 95% CI 1.24-2.45; P<0.001) and in-hospital worsening renal function in acute heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: